123 related articles for article (PubMed ID: 30415242)
1. Clinicopathologic charcterization of sorafenib-induced endoplasmic reticulum stress in human liver cancer cells.
Liu M; Zhou R; Wu X; Xu X; Su M; Yang B
J Physiol Pharmacol; 2018 Aug; 69(4):. PubMed ID: 30415242
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
3. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
4. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach.
Hosseinzadeh F; Ai J; Hajifathali A; Muhammadnejad S; Ebrahimi-Barough S; Seyhoun I; Komeili Movahed T; Shirian S; Hosseinzadeh F; Ahmadpour S; Alijani M; Verdi J
Pharmacol Rep; 2022 Apr; 74(2):379-391. PubMed ID: 35089543
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C
Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Phan C; Zheng Z; Wang J; Wang Q; Hu X; Tang G; Bai H
Biomater Sci; 2019 Nov; 7(11):4758-4768. PubMed ID: 31509117
[TBL] [Abstract][Full Text] [Related]
7. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
8. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
[TBL] [Abstract][Full Text] [Related]
9. COLEC10 Induces Endoplasmic Reticulum Stress by Occupying GRP78 and Inhibits Hepatocellular Carcinoma.
Cai MN; Chen DM; Xiao LX; Li SS; Liao CH; Li J; Huang ZX; Wang JL; Gu YR; Gu L; Huang YH; Lian YF
Lab Invest; 2023 Jul; 103(7):100130. PubMed ID: 36925047
[TBL] [Abstract][Full Text] [Related]
10. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis.
Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC
Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935
[TBL] [Abstract][Full Text] [Related]
11. Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells.
Montalbano R; Honrath B; Wissniowski TT; Elxnat M; Roth S; Ocker M; Quint K; Churin Y; Roederfeld M; Schroeder D; Glebe D; Roeb E; Di Fazio P
Oncotarget; 2016 Apr; 7(15):20312-23. PubMed ID: 26967385
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib- Taurine Combination Model for Hepatocellular Carcinoma Cells: Immunological Aspects.
Afifi AM; El-Husseiny AM; Tabashy RH; Khalil MA; El-Houseini ME
Asian Pac J Cancer Prev; 2019 Oct; 20(10):3007-3013. PubMed ID: 31653148
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of selective internal radiotherapy versus sorafenib for intermediate-locally advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Zou J; Zhu W; Meng H; Luo P; Zhang J
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):271-279. PubMed ID: 30791765
[TBL] [Abstract][Full Text] [Related]
14. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action.
Elmetwalli A; Diab T; Albalawi AN; El-Naggar SA; El-Far AH; Ghedan AR; Alamri ES; Salama AF
Naunyn Schmiedebergs Arch Pharmacol; 2023 Oct; 396(10):2501-2517. PubMed ID: 37145126
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
16. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Ma MKF; Lau EYT; Leung DHW; Lo J; Ho NPY; Cheng LKW; Ma S; Lin CH; Copland JA; Ding J; Lo RCL; Ng IOL; Lee TKW
J Hepatol; 2017 Nov; 67(5):979-990. PubMed ID: 28647567
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum stress and oxidative stress are involved in ZnO nanoparticle-induced hepatotoxicity.
Yang X; Shao H; Liu W; Gu W; Shu X; Mo Y; Chen X; Zhang Q; Jiang M
Toxicol Lett; 2015 Apr; 234(1):40-9. PubMed ID: 25680694
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages promote resistance of hepatocellular carcinoma cells against sorafenib by activating CXCR2 signaling.
Wang HC; Haung LY; Wang CJ; Chao YJ; Hou YC; Yen CJ; Shan YS
J Biomed Sci; 2022 Nov; 29(1):99. PubMed ID: 36411463
[TBL] [Abstract][Full Text] [Related]
19. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
